These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 38047833)

  • 21. Promising clinical efficacy of streptomycin-rifampin combination for treatment of buruli ulcer (Mycobacterium ulcerans disease).
    Chauty A; Ardant MF; Adeye A; Euverte H; Guédénon A; Johnson C; Aubry J; Nuermberger E; Grosset J
    Antimicrob Agents Chemother; 2007 Nov; 51(11):4029-35. PubMed ID: 17526760
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Local and regional re-establishment of cellular immunity during curative antibiotherapy of murine Mycobacterium ulcerans infection.
    Martins TG; Gama JB; Fraga AG; Saraiva M; Silva MT; Castro AG; Pedrosa J
    PLoS One; 2012; 7(2):e32740. PubMed ID: 22393444
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The compound TB47 is highly bactericidal against Mycobacterium ulcerans in a Buruli ulcer mouse model.
    Liu Y; Gao Y; Liu J; Tan Y; Liu Z; Chhotaray C; Jiang H; Lu Z; Chiwala G; Wang S; Makafe G; Islam MM; Hameed HMA; Cai X; Wang C; Li X; Tan S; Zhang T
    Nat Commun; 2019 Jan; 10(1):524. PubMed ID: 30705268
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Microbiology of secondary infections in Buruli ulcer lesions; implications for therapeutic interventions.
    Gyamfi E; Narh CA; Quaye C; Abbass A; Dzudzor B; Mosi L
    BMC Microbiol; 2021 Jan; 21(1):4. PubMed ID: 33402095
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Overview: Development of Drugs Against Mycobacterium ulcerans.
    Pluschke G; Röltgen K
    Methods Mol Biol; 2022; 2387():185-187. PubMed ID: 34643912
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Amoxicillin/clavulanate in combination with rifampicin/clarithromycin is bactericidal against Mycobacterium ulcerans.
    Sáez-López E; Millán-Placer AC; Lucía A; Ramón-García S
    PLoS Negl Trop Dis; 2024 Apr; 18(4):e0011867. PubMed ID: 38573915
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Unlocking Opportunities for
    Shyam M; Kumar S; Singh V
    ACS Infect Dis; 2024 Feb; 10(2):251-269. PubMed ID: 38295025
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Corticosteroid-induced immunosuppression ultimately does not compromise the efficacy of antibiotherapy in murine Mycobacterium ulcerans infection.
    Martins TG; Trigo G; Fraga AG; Gama JB; Longatto-Filho A; Saraiva M; Silva MT; Castro AG; Pedrosa J
    PLoS Negl Trop Dis; 2012; 6(11):e1925. PubMed ID: 23209864
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Buruli ulcer (Mycobacterium ulcerans infection).
    Walsh DS; Portaels F; Meyers WM
    Trans R Soc Trop Med Hyg; 2008 Oct; 102(10):969-78. PubMed ID: 18657836
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Secondary Buruli ulcer skin lesions emerging several months after completion of chemotherapy: paradoxical reaction or evidence for immune protection?
    Ruf MT; Chauty A; Adeye A; Ardant MF; Koussemou H; Johnson RC; Pluschke G
    PLoS Negl Trop Dis; 2011 Aug; 5(8):e1252. PubMed ID: 21829740
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Buruli ulcer in West Africa: strategies for early detection and treatment in the antibiotic era.
    Webb BJ; Hauck FR; Houp E; Portaels F
    East Afr J Public Health; 2009 Aug; 6(2):144-7. PubMed ID: 20000019
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of Rifampin Plus Clofazimine in a Murine Model of Mycobacterium ulcerans Disease.
    Converse PJ; Tyagi S; Xing Y; Li SY; Kishi Y; Adamson J; Nuermberger EL; Grosset JH
    PLoS Negl Trop Dis; 2015; 9(6):e0003823. PubMed ID: 26042792
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Paradoxical reactions and responses during antibiotic treatment for Mycobacterium ulcerans infection (Buruli ulcer). Four cases from French Guiana].
    Sambourg E; Dufour J; Edouard S; Morris A; Mosnier E; Reynaud Y; Sainte-Marie D; Nacher M; Guégan JF; Couppié P
    Ann Dermatol Venereol; 2014; 141(6-7):413-8. PubMed ID: 24951139
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phage therapy is effective against infection by Mycobacterium ulcerans in a murine footpad model.
    Trigo G; Martins TG; Fraga AG; Longatto-Filho A; Castro AG; Azeredo J; Pedrosa J
    PLoS Negl Trop Dis; 2013; 7(4):e2183. PubMed ID: 23638204
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Comparison of inhibitory effect of rifalazil and rifampicin against Mycobacterium ulcerans infection induced in mice].
    Nakanaga K; Saito H; Ishii N; Goto M
    Kekkaku; 2004 May; 79(5):333-9. PubMed ID: 15211873
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Buruli ulcer: Advances in understanding Mycobacterium ulcerans infection.
    Walsh DS; Portaels F; Meyers WM
    Dermatol Clin; 2011 Jan; 29(1):1-8. PubMed ID: 21095521
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interferon-γ Is a Crucial Activator of Early Host Immune Defense against Mycobacterium ulcerans Infection in Mice.
    Bieri R; Bolz M; Ruf MT; Pluschke G
    PLoS Negl Trop Dis; 2016 Feb; 10(2):e0004450. PubMed ID: 26863011
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Activities of rifampin, Rifapentine and clarithromycin alone and in combination against mycobacterium ulcerans disease in mice.
    Almeida D; Converse PJ; Ahmad Z; Dooley KE; Nuermberger EL; Grosset JH
    PLoS Negl Trop Dis; 2011 Jan; 5(1):e933. PubMed ID: 21245920
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of 8 weeks standard treatment (rifampicin plus clarithromycin) vs. 4 weeks standard plus amoxicillin/clavulanate treatment [RC8 vs. RCA4] to shorten Buruli ulcer disease therapy (the BLMs4BU trial): study protocol for a randomized controlled multi-centre trial in Benin.
    Johnson RC; Sáez-López E; Anagonou ES; Kpoton GG; Ayelo AG; Gnimavo RS; Mignanwande FZ; Houezo JG; Sopoh GE; Addo J; Orford L; Vlasakakis G; Biswas N; Calderon F; Della Pasqua O; Gine-March A; Herrador Z; Mendoza-Losana A; Díez G; Cruz I; Ramón-García S
    Trials; 2022 Jul; 23(1):559. PubMed ID: 35804454
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oxazolidinones Can Replace Clarithromycin in Combination with Rifampin in a Mouse Model of Buruli Ulcer.
    Almeida DV; Omansen TF; Li SY; Lee J; Grosset JH; Converse PJ; Nuermberger EL
    Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30559131
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.